Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

NCT01907854 · Completed

Last updated 2026-05-28

This clinical trial tested whether adults with type 2 diabetes, whose blood sugar was not well controlled on sitagliptin and metformin, could benefit from switching to liraglutide.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 407 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-12 · est. completion 2015-06

Where 106 sites · Canada, Hungary, India, Israel, Puerto Rico, Spain, United States

What this study is testing ClinicalTrials.gov NCT01907854 ↗

Description as written by the study sponsor.

This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.

Treatments tested

liraglutide Drug

Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
sitagliptin Drug

100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
placebo Drug

Sitagliptin placebo tablets once-daily
placebo Drug

Sitagliptin placebo tablets once-daily

Main thing measured	Change in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01907854 ↗